Clinical Trials Browser

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT02883062 2026-04-13

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

Phase 2 Active not recruiting

67 enrolled 16 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03598257 2026-04-13

Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer

Phase 2 Active not recruiting

300 enrolled

Breast

Inflammatory Breast Neoplasms

NCT03650894 2026-04-13

Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients

Phase 2 Active not recruiting

30 enrolled

Breast

Breast Neoplasms

NCT04090398 2026-04-13

Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones

Phase 2 Active not recruiting

70 enrolled

BreastOther neoplasm

Anatomic Stage IV Breast Cancer AJCC v8

NCT04225117 2026-04-13

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Phase 2 Active not recruiting

329 enrolled 23 charts

BreastGastrointestinalHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Triple Negative Breast Neoplasms

NCT04553133 2026-04-13

PF-07104091 as a Single Agent and in Combination Therapy

Phase 2 Active not recruiting

157 enrolled

BreastGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Small Cell Lung Carcinoma

NCT06702618 2026-04-09

Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer

Phase 2 Active not recruiting

33 enrolled

Breast

Breast Neoplasms

NCT04524000 2026-04-08

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer

Phase 2 Active not recruiting

24 enrolled

Breast

Advanced Breast Cancer

NCT06604858 2026-04-07

TELESCOPE

Phase 2 Active not recruiting

31 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03428802 2026-04-03

Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability

Phase 2 Active not recruiting

21 enrolled 9 charts

BreastGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms

NCT03678883 2026-04-03

9-ING-41 in Patients With Advanced Cancers

Phase 2 Active not recruiting

350 enrolled

BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT05710328 2026-04-03

Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial

Phase 2 Active not recruiting

235 enrolled

Breast

Anatomic Stage II Breast Cancer AJCC v8

NCT04544189 2026-04-02

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer

Phase 2 Active not recruiting

69 enrolled

Breast

Breast Neoplasms

NCT04569747 2026-04-02

ADEPT

Phase 2 Active not recruiting

393 enrolled

Breast

Breast Neoplasms

NCT02890082 2026-03-31

PRESAGE

Phase 2 Active not recruiting

102 enrolled

Breast

Breast Neoplasms

NCT04067726 2026-03-31

TRIDENT

Phase 2 Active not recruiting

210 enrolled

Breast

Breast Neoplasms

NCT01525966 2026-03-30

Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer

Phase 2 Active not recruiting

67 enrolled 12 charts

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03546686 2026-03-27

Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer

Phase 2 Active not recruiting

51 enrolled

Breast

Breast Neoplasms

NCT02422498 2026-03-24

Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy

Phase 2 Active not recruiting

49 enrolled 8 charts

Breast

Triple Negative Breast Neoplasms

NCT04266249 2026-03-23

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

Phase 2 Active not recruiting

2,175 enrolled

Breast

Anatomic Stage II Breast Cancer AJCC v8

NCT04316117 2026-03-23

Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study

Phase 2 Active not recruiting

138 enrolled

Breast

Breast Neoplasms

NCT04576455 2026-03-20

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

Phase 2 Active not recruiting

303 enrolled 23 charts

Breast

Breast Neoplasms

NCT06188559 2026-03-20

A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer

Phase 2 Active not recruiting

135 enrolled

Breast

Breast Neoplasms

NCT03573648 2026-03-19

ImmunoADAPT

Phase 2 Active not recruiting

33 enrolled

Breast

Breast Neoplasms

NCT04899908 2026-03-19

Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases

Phase 2 Active not recruiting

134 enrolled

BreastCNSDermatologicGastrointestinalThoracic

Brain Neoplasms, Breast Neoplasms, Gastrointestinal Neoplasms, Lung Neoplasms, Melanoma, Colorectal Neoplasms

NCT02482376 2026-03-17

Preoperative Single-Fraction Radiotherapy in Early Stage Breast Cancer

Phase 2 Active not recruiting

110 enrolled 18 charts

Breast

Breast Neoplasms

NCT05227664 2026-03-16

A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer

Phase 2 Active not recruiting

120 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05852691 2026-03-16

A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

Phase 2 Active not recruiting

83 enrolled

Breast

Breast Neoplasms

NCT04001829 2026-03-13

Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer

Phase 2 Active not recruiting

249 enrolled 14 charts

Breast

Anatomic Stage I Breast Cancer AJCC v8

NCT07471815 2026-03-13

Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy

Phase 2 Active not recruiting

30 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04293393 2026-03-12

CARABELA

Phase 2 Active not recruiting

200 enrolled 27 charts

Breast

Breast Neoplasms

NCT05865990 2026-03-12

TUXEDO-3

Phase 2 Active not recruiting

63 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms, Meningeal Neoplasms

NCT01266642 2026-03-11

Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer

Phase 2 Active not recruiting

301 enrolled 9 charts

Breast

Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT02712723 2026-03-11

FELINE

Phase 2 Active not recruiting

121 enrolled 9 charts

Breast

Breast Neoplasms

NCT03330847 2026-03-10

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

Phase 2 Active not recruiting

273 enrolled 22 charts

Breast

Triple Negative Breast Neoplasms

NCT05810870 2026-03-10

SABINA

Phase 2 Active not recruiting

14 enrolled

Breast

Breast Neoplasms

NCT06048718 2026-03-10

TUXEDO-4

Phase 2 Active not recruiting

28 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT01334021 2026-03-09

Genetic Testing in Predicting Tumor Response in Patients With Stage I-III HER2 Negative Invasive Breast Cancer

Phase 2 Active not recruiting

1,100 enrolled

Breast

Anatomic Stage I Breast Cancer AJCC v8

NCT04829604 2026-03-09

ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)

Phase 2 Active not recruiting

72 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT02568267 2026-03-06

STARTRK-2

Phase 2 Active not recruiting

534 enrolled 2 FDA

BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidNETSarcomaThoracic

Thyroid Cancer, Papillary, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Colorectal Neoplasms, Lymphoma, Large-Cell, Anaplastic, Cholangiocarcinoma, Neuroendocrine Tumors

NCT03384914 2026-03-06

Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer

Phase 2 Active not recruiting

119 enrolled

Breast

Breast Neoplasms, Neoplasm, Residual, Breast Neoplasms, Male

Clinical Trials

T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA

InCITe

Electroacupuncture Therapy in Reducing Chronic Pain in Patients After Breast Cancer Treatment

Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer

Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer

FAIM

Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer

FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer

Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients

Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

PF-07104091 as a Single Agent and in Combination Therapy

Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer

TELESCOPE

Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability

9-ING-41 in Patients With Advanced Cancers

Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer

ADEPT

PRESAGE

TRIDENT

Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer

Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer

Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer

ImmunoADAPT

Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases

Preoperative Single-Fraction Radiotherapy in Early Stage Breast Cancer

A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer

A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer

Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy

CARABELA

TUXEDO-3

Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer

FELINE

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

SABINA

TUXEDO-4

Genetic Testing in Predicting Tumor Response in Patients With Stage I-III HER2 Negative Invasive Breast Cancer

ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)

STARTRK-2

Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer